AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
ritodrine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| sympathomimetics | 2390 | 26652-09-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An adrenergic beta-2 agonist used to control PREMATURE LABOR.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 40 | mg | O |
| 40 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
| EoM (Fraction excreted unchanged in urine) | 10 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 5.97 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 30 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 4.40 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 31 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.64 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.60 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 65 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,ZAP70 | 38 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,ACVRL1,AXL,BRAF,CAMK2B,CAMK2D,CDK4,CDK9,DYRK1B,EIF2AK3,EPHB4,GRK2,JAK2,MAP2K6,MAPK12,PRKCD,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,ULK1,ULK2 | 25 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 22, 1991 | FDA | HOSPIRA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Maternal exposure during pregnancy | 216.48 | 176.74 | 80 | 467 | 359983 | 90267917 |
| Exposure during pregnancy | 207.86 | 176.74 | 70 | 477 | 238340 | 90389560 |
| Premature delivery | 188.46 | 176.74 | 44 | 503 | 38718 | 90589182 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Exposure during pregnancy | 232.95 | 165.30 | 62 | 324 | 167362 | 110421551 |
| Maternal exposure during pregnancy | 229.47 | 165.30 | 67 | 319 | 254816 | 110334097 |
| Premature delivery | 199.23 | 165.30 | 40 | 346 | 30592 | 110558321 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G02CA01 | GENITO URINARY SYSTEM AND SEX HORMONES OTHER GYNECOLOGICALS OTHER GYNECOLOGICALS Sympathomimetics, labour repressants |
| MeSH PA | D000318 | Adrenergic beta-Agonists |
| MeSH PA | D012102 | Reproductive Control Agents |
| MeSH PA | D013566 | Sympathomimetics |
| MeSH PA | D015149 | Tocolytic Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D058666 | Adrenergic beta-2 Receptor Agonists |
Related Drugs by ATC class:
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Premature labor | indication | 6383007 | |
| Chorioamnionitis | contraindication | 11612004 | |
| Gestational diabetes mellitus | contraindication | 11687002 | DOID:11714 |
| Hypovolemia | contraindication | 28560003 | |
| Dehydration | contraindication | 34095006 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Antepartum hemorrhage | contraindication | 34842007 | |
| Migraine | contraindication | 37796009 | DOID:6364 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Mild pre-eclampsia | contraindication | 41114007 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Severe pre-eclampsia | contraindication | 46764007 | |
| Pulmonary hypertension | contraindication | 70995007 | DOID:6432 |
| Eclampsia in pregnancy | contraindication | 198992004 | |
| Fetal death | contraindication | 276507005 | |
| Hypertensive urgency | contraindication | 443482000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.35 | acidic |
| pKa2 | 11.01 | acidic |
| pKa3 | 8.82 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Beta-2 adrenergic receptor | GPCR | AGONIST | EC50 | 7.62 | WOMBAT-PK | CHEMBL | |||
| Beta-3 adrenergic receptor | GPCR | EC50 | 6.72 | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4019928 | VUID |
| N0000148013 | NUI |
| D01263 | KEGG_DRUG |
| 4018621 | VANDF |
| 4019928 | VANDF |
| C0035661 | UMLSCUI |
| CHEBI:8872 | CHEBI |
| CHEMBL83063 | ChEMBL_ID |
| CHEMBL1367605 | ChEMBL_ID |
| DB00867 | DRUGBANK_ID |
| D012312 | MESH_DESCRIPTOR_UI |
| 33572 | PUBCHEM_CID |
| 7294 | IUPHAR_LIGAND_ID |
| 2608 | INN_ID |
| 23239-51-2 | SECONDARY_CAS_RN |
| I0Q6O6740J | UNII |
| 105470 | RXNORM |
| 1276 | MMSL |
| 1407 | MMSL |
| 5430 | MMSL |
| d00603 | MMSL |
| 001813 | NDDF |
| 004732 | NDDF |
| 372893009 | SNOMEDCT_US |
| 86257005 | SNOMEDCT_US |
| 89785009 | SNOMEDCT_US |
| I0Q6O6740J | INXIGHT DRUGS |
Pharmaceutical products:
None